Navigation Links
Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd
Date:7/14/2008

ls, filter out many viruses, parasites, and other biotoxins as well. The DSU is in a pilot-use program at a major U.S. medical center and has been selected for further development by the U.S. Marine Corps.

For more information on Nephros, please visit the Company's website at http://www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros's control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain funding if and when needed or on favorable terms; (ii) to continue as a going concern; (iii) to liquidate its short-term investments when needed to fund its operations; (iv) to maintain compliance with the AMEX's continued listing standards; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; (vi) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (vii) to have its technologies and products accepted in current or future target markets; or (viii) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the
'/>"/>

SOURCE Nephros, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Nephros Appoints Gerald J. Kochanski as Chief Financial Officer
2. BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals
3. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
4. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
5. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
6. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
7. Maryland Stem Cell Research Commission Recommends 62 Projects for Funding
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Avicena Group to Present at Noble Financial Conference
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Tooth decay is ... showing active signs of the disease. The World Health Organization ... nearly 100% of adults have cavities. What are the long-term ... is showing a strong connection between the oral bacterial imbalance ... this disease so rampant, yet it is also 100% preventable? ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... , , SOUTH PLAINFIELD, ... the initiation of a Phase 3 trial of ataluren (formerly ... mutation cystic fibrosis (nmCF). Patients with CF lack adequate ... a chloride channel necessary for normal function of the lung, ...
... , , INDIANAPOLIS, Sept. 10 ... Advanced lithium-ion battery maker EnerDel, Inc. today named Richard L. Stanley ... global manufacturing and management experience and a distinguished record of creating ... appointments designed to position EnerDel for continued success in the next ...
... , OXFORD, England, September ... Watkins as Head of the Product & Portfolio,Strategy ... Senior Advisors,and Analysts. , ... "We are,delighted to welcome Nikki to PharmaVentures. Our ...
Cached Biology Technology:PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6Lithium-Ion Battery Maker Names New President 2Lithium-Ion Battery Maker Names New President 3Lithium-Ion Battery Maker Names New President 4Lithium-Ion Battery Maker Names New President 5Lithium-Ion Battery Maker Names New President 6PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy 2
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
(Date:5/15/2013)... gout risk, new research reveals that vitamin C, also ... levels to a clinically significant degree in patients with ... with allopurinol, appears to have a weak effect on ... the results published in the American College of Rheumatology ... Gout is an inflammatory arthritis that causes excruciating pain ...
(Date:5/15/2013)... to date to examine the efficacy of PARP inhibitor ... breast and ovarian cancer, the oral drug olaparib was ... cancers. Results of the study, led by researchers from ... Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, ... Oncology,s annual meeting in Chicago in early June (Abstract ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... MADISON, WI, September 29, 2008 A plot of ... 110 years of sustainable farming practices can produce similar ... In 1896, Professor J.F. Duggar at the Agricultural ... an experiment to test his theories that sustainable cotton ...
... video clip of Leonard Kleinrock showing his contributions to ... George W. Bush will award the National Medals of ... leading researchers, inventors and innovators, at a ceremony in ... a.m. on Monday, September 29, 2008. Reporters interested in ...
... that inexpensive device boosts fuel economy by up to 20 ... prices, researchers in Pennsylvania are reporting results of laboratory tests ... to a car engine,s fuel injector can boost gas mileage ... precious miles per gallon, they say. Their study is scheduled ...
Cached Biology News:Experiment demonstrates 110 years of sustainable agriculture 28 National Medals of Science awardees to be honored at gala, then the White House 28 National Medals of Science awardees to be honored at gala, then the White House 38 National Medals of Science awardees to be honored at gala, then the White House 48 National Medals of Science awardees to be honored at gala, then the White House 58 National Medals of Science awardees to be honored at gala, then the White House 68 National Medals of Science awardees to be honored at gala, then the White House 78 National Medals of Science awardees to be honored at gala, then the White House 8American Chemical Society's Weekly PressPac -- Sept. 24, 2008 2American Chemical Society's Weekly PressPac -- Sept. 24, 2008 3American Chemical Society's Weekly PressPac -- Sept. 24, 2008 4American Chemical Society's Weekly PressPac -- Sept. 24, 2008 5American Chemical Society's Weekly PressPac -- Sept. 24, 2008 6American Chemical Society's Weekly PressPac -- Sept. 24, 2008 7American Chemical Society's Weekly PressPac -- Sept. 24, 2008 8
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: